Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceftazidime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.88 |
| ▸ | PPARG | P37231 | 3/20 | 0.88 |
| ▸ | PGR | P06401 | 3/20 | 0.88 |
| ▸ | ESR1 | P03372 | 1/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.63 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.63 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.57 |
| ▸ | APEX1 | P27695 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceftazidime SCHEMBL1237405 | 1.00 | NR1I2 (0.88) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL12968439 | 0.99 | NR1I2 (0.90) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL22368513 | 0.99 | NR1I2 (0.90) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL12374441 | 0.99 | NR1I2 (0.90) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL13451860 | 0.99 | NR1I2 (0.90) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL7639337 | 0.99 | NR1I2 (0.88) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL20603076 | 0.99 | NR1I2 (0.88) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL27993281 | 0.99 | NR1I2 (0.88) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL29120318 | 0.97 | NR1I2 (0.86) | NR1I2PPARGPGRESR1TDP1 | |
| Ceftazidime SCHEMBL5594295 | 0.95 | NR1I2 (0.95) | NR1I2PPARGPGRESR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724919-A | Preparation method of cefvicin sodium double-side chain impurity | 艾美科健（中国）生物医药有限公司 | 2024-10-01 | — | — | CN | claimed |
| US-20220362327-A1 | COMPOSITIONS AND METHODS FOR WOUND HEALING | DIAB NASSER (US) | 2022-11-17 | — | — | US | claimed |
| CN-115252561-A | Preparation method of ceftazidime avibactam sodium for injection | 海南通用三洋药业有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-112450219-A | Abamebactam and beta-lactam antibiotic compound synergistic composition | 广西壮族自治区农业科学院 | 2021-03-09 | — | — | CN | claimed |
| US-10874771-B2 | Oriented P4HB implants containing antimicrobial agents | TEPHA, INC. (US) | 2020-12-29 | — | — | US | claimed |
| WO-2018025248-A1 | EDTA INJECTION AND PROCESS FOR MAKING THE SAME | JODAS EXPOIM PRIVATE LIMITED (IN) | 2018-02-08 | — | — | WO | claimed |
| CN-102091073-A | Ceftazidime and tazobactam sodium medicine composition liposome injection | MING WANG | 2011-06-15 | — | — | CN | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20260061030-A1 | COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS | BIOAEGIS THERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| CN-115724855-B | Continuous preparation method of ceftazidime | 华北制药河北华民药业有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119464405-A | Method for synthesizing cefvia mother nucleus by enzyme method | 华北制药集团动物保健品有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12194049-B2 | Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection | GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD. (CN) | 2025-01-14 | — | — | US | disclosed |
| CN-119136783-A | Buffer-containing compositions and methods of use thereof | 诺欧生物有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-1438905-A | Microneedle to deliver the substance to the dermis | BECTON DICKINSON CO (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1317933-A1 | PREPARATIONS FOR COATING WOUND | SSP Co., Ltd. (JP) | 2003-06-11 | — | — | EP | disclosed |
| EP-0791597-B1 | Method for manufacture of cephalosporins and intermediates thereof | LUPIN LAB LTD (IN) | 2000-07-12 | — | — | EP | disclosed |
| US-5831085-A | Process for manufacture of cephalosporin such as ceftazidime and intermediate thereof | LUPIN LABORATORIES LIMITED (IN) | 1998-11-03 | — | — | US | disclosed |
| EP-0791597-A1 | Method for manufacture of cephalosporins and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061030-A1 | COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS | SLC11A2, GSDMD, C5 | NR1I2 3599/4885PPARG 2717/4885PGR 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.